Crossmark

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s13014-021-01795-5

Published Online: 2021-04-09

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Charles https://orcid.org/0000-0001-5589-4775
Ballah, Trishna

Nottage, Michelle

Hay, Karen

Chua, Benjamin

Kenny, Lizbeth

Thomas, Paul

Teng, Michele

Keller, Jacqui

Le, Trang

Edmunds, Jennifer

Hughes, Brett
Funding

Funding for this research was provided by:

AstraZeneca Australia
License Information

Text and Data Mining valid from 2021-04-09

Version of Record valid from 2021-04-09
More Information

Article History

Received: 3 October 2020

Accepted: 23 March 2021

First Online: 9 April 2021

Declarations

:

: This study has been reviewed and approved by the RBWH HREC (EC00172).

: Not applicable. There is no individual person’s data in any form in this manuscript.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below